HappyLibrarian,
One thing to consider is that “optimizing the process” at Advent is considered experimental so very likely Specials only off sets annual contracted payment agreement to Advent by some minuscule amount at this time which is not what many expected from Specials. I am also thinking that the ~€200,000 required for treatment probably includes quite a bit of medical cost associated with the doctor visits, leukopheresis, administration of L and followup, not just what Advent and NWBO would receive.
At some near term point after submission I would expect more clarity about Specials income as that should not be hidden at that point. There also needs to be an explanation about pending contract manufacturing agreements once submission is made as I believe that must be planned for in advance of approval(s). Best wishes.
Market Data 
Markets 
AI
